source
- Jaguar LAA acquires Johnson & Johnson's Laminar atrial fibrillation device assetsJaguar LAA, a newly formed medtech company, announced it has purchased assets related to Johnson & Johnson's Laminar atrial fibrillation device program. The Laminar technology is a catheter‑based…
- Summit and Akeso report ivonescimab extends lung cancer survival by eight months versus Keytruda in Phase 3 trialSummit Therapeutics and its partner Akeso said their experimental dual-target drug ivonescimab added about eight months of overall survival for patients with lung cancer compared with Merck's Keytr…